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Impact of polygenic schizophrenia-related risk and
hippocampal volumes on the onset of psychosis
F Harrisberger1,2, R Smieskova1,2,3, C Vogler2,4, T Egli4, A Schmidt5, C Lenz1,2, AE Simon6, A Riecher-Rössler1,2,
A Papassotiropoulos2,4,7,8 and S Borgwardt1,2,3,5
Alterations in hippocampal volume are a known marker for ﬁrst-episode psychosis (FEP) as well as for the clinical high-risk state. The
Polygenic Schizophrenia-related Risk Score (PSRS), derived from a large case–control study, indicates the polygenic predisposition
for schizophrenia in our clinical sample. A total of 65 at-risk mental state (ARMS) and FEP patients underwent structural magnetic
resonance imaging. We used automatic segmentation of hippocampal volumes using the FSL-FIRST software and an odds-ratio-
weighted PSRS based on the publicly available top single-nucleotide polymorphisms from the Psychiatric Genomics Consortium
genome-wide association study (GWAS). We observed a negative association between the PSRS and hippocampal volumes
(β=− 0.42, P= 0.01, 95% conﬁdence interval (CI) = (−0.72 to − 0.12)) across FEP and ARMS patients. Moreover, a higher PSRS was
signiﬁcantly associated with a higher probability of an individual being assigned to the FEP group relative to the ARMS group
(β= 0.64, P= 0.03, 95% CI = (0.08–1.29)). These ﬁndings provide evidence that a subset of schizophrenia risk variants is negatively
associated with hippocampal volumes, and higher values of this PSRS are signiﬁcantly associated with FEP compared with the
ARMS. This implies that FEP patients have a higher genetic risk for schizophrenia than the total cohort of ARMS patients. The
identiﬁcation of associations between genetic risk variants and structural brain alterations will increase our understanding of the
neurobiology underlying the transition to psychosis.
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INTRODUCTION
Schizophrenia can be a severe mental disorder, affecting ~ 1% of
the population.1 Although the pathophysiological mechanisms
underlying schizophrenia are still poorly understood, it is known
that genetic factors and combinations thereof (that is, single-
nucleotide polymorphisms (SNP), copy-number variations or
mutations) are involved in disease aetiology, as is indicated by
the substantial heritability estimates for schizophrenia.2 Moreover,
in combination with environmental trigger factors, it might lead to
the transition to psychosis from the clinical high-risk state. Around
30% of clinical at-risk mental state (ARMS) individuals will make a
transition to psychosis within the subsequent 2 years.3–5 Finding
markers that further characterise these ARMS individuals is the
main goal of psychiatric research, as early treatment of this group
is thought to prevent or delay the onset of a ﬁrst episode of
psychosis.6,7 Several markers besides clinical characteristics
describe prodromal psychosis, for example, structural and
functional brain alterations or cognitive functioning.8,9 Even in
the ARMS, neuroimaging observations revealed reductions in the
grey matter of the medial temporal lobe, including the
hippocampus,10–14 as well as neurofunctional aberrations within
the hippocampus15 and deﬁcits in verbal ﬂuency and memory
functioning.16 However, results are inconsistent in the differences
in hippocampal volume between ﬁrst-episode psychosis (FEP)
patients and ARMS individuals, regardless of future transition to
psychosis.10,11,17 Moreover, hippocampal volumes were shown to
be highly heritable in twin studies of healthy individuals;18,19
however, twin studies where one of the twins was affected by
schizophrenia also revealed substantial modulation of hippocam-
pal volumes by environmental factors.20–23 In addition, moderate
genetic heritability of the hippocampal volumes was shown in
large extended families affected with schizophrenia.24
Although individual effects of SNPs on the genetic risk for
schizophrenia were found to be small, it was estimated that 23%
of variation in liability to schizophrenia is captured by SNPs with a
substantial proportion of this variation attributed to common
causal variants.25,26 The largest genome-wide association study
(GWAS), performed by the Psychiatric Genomic Consortium (PGC),
identiﬁed 108 schizophrenia-associated loci,27 which explained up
to 3.4% of the phenotypic variance in case–control studies. In
general, the combination of GWAS-signiﬁcant risk SNPs, the
Polygenic Schizophrenia-related Risk Score (PSRS), describes the
estimated cumulative genomic risk for schizophrenia.
Only a few studies have reported associations between a PSRS
and brain volumes. All of these studies investigated the above-
mentioned association in different cohorts of schizophrenia
patients, their relatives and/or healthy controls.28–30 They found
association of a PSRS with total brain volume,28 especially with
white matter volume.28,29 Unfortunately, these results could not
be replicated in another independent sample.30 However, none of
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these studies investigated the association of a PSRS with brain
volume in ARMS individuals and FEP patients. Moreover, a GWAS
identiﬁed single SNPs linked to hippocampal volume in healthy
controls;18 however, no study to date has investigated the
association of a PSRS with volumetric differences in this region.
On the basis of ﬁndings supporting a role for hippocampal
alterations in FEP and even in the ARMS,10–14 we aimed to explore
the association between the PSRS, hippocampal volume and the
onset of psychosis. The identiﬁcation of associations between
genetic risk variants and structural alterations will increase our
understanding of the neurobiology underlying psychosis, as well
as the transition to psychosis. Linking the PSRS to structural
alterations in the brain will be helpful in elucidating the
neurobiology underlying psychosis and may also increase our
understanding of the factors contributing to the transition to
psychosis in ARMS individuals. We hypothesised that a higher
PSRS is associated with both smaller hippocampal volumes and
the probability of being FEP.
MATERIALS AND METHODS
Participants and clinical assessment
Individuals included in this study were recruited via the early detection of
psychosis research programme at the Psychiatry Outpatient Department,
Psychiatric University Clinics Basel5,31 and were either ARMS individuals or
FEP patients. All individuals were assessed using the Basel Screening
Instrument for Psychosis,32 the Brief Psychiatric Rating Scale (BPRS), the
Scale for the Assessment of Negative Symptoms (SANS) and the Global
Assessment of Functioning (GAF) at the time of the magnetic resonance
imaging scan. We additionally obtained information on current and
previous psychotropic medication, nicotine and illegal drug consumption
using a semistructured interview adapted from the Early Psychosis
Prevention and Intervention Centre Drug and Alcohol Assessment
Schedule (eppic.org.au).
ARMS was deﬁned in accordance with the criteria by Yung et al.33 and
resulted in the inclusion of N= 43 ARMS individuals in the study. Thus,
inclusion required one or more of the following: (a) 'attenuated' psychotic
symptoms, (b) brief limited intermittent psychotic symptoms or (c) a ﬁrst-
or second-degree relative with a psychotic disorder plus at least two
indicators of a clinical change, according to the Basel Screening Instrument
for Psychosis.31,34 Inclusion because of criterion (a) required a change in
the mental state at least several times a week and for more than 1 week (a
score of 2 or 3 on the BPRS hallucination item or 3 or 4 on BPRS items for
unusual thought content or suspiciousness). Inclusion because of (b)
required BPRS scores of ⩾ 4 on the hallucination item or ⩾ 5 on the unusual
thought content, suspiciousness or conceptual disorganisation items, with
each symptom lasting less than 1 week before resolving spontaneously.
None of the included subjects fulﬁlled criterion (c). All individuals were
antipsychotic-naive at the time of scanning, whereas 18 of the ARMS
individuals were receiving antidepressants.
The FEP patients (N= 36) met the operational criteria according to Yung
et al.,33 and they fulﬁlled criteria for acute psychotic disorder according to
International Statistical Classiﬁcation of Diseases, 10th Revision (ICD-10) or
Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)
but not for schizophrenia. Inclusion required scores of ⩾ 4 on the
hallucination item or ⩾ 5 on the unusual thought content, suspiciousness
or conceptual disorganisation items of the BPRS. The symptoms had to
have occurred at least several times a week and persisted for more than
1 week. Fourteen of our FEP patients were antipsychotic-naive, three
were antipsychotic-free and ten were receiving antipsychotic medication
at the time of scanning (three quetiapine, three risperidone, two
olanzapine, one clozapine and one aripiprazole). In the antipsychotic-free
group, antipsychotic medication (two risperidone and one aripiprazole)
has been stopped 4, 19 and 24 months previously. Antipsychotic dose was
converted into chlorpromazine (CPZ) equivalents using the Supplementary
Table Antipsychotic dose conversion by Ho et al.35 The mean CPZ
equivalents (s.d.) were 227.39 (202.90). Of all FEP patients, three received
only antidepressants and four were on a combined treatment with
antidepressants and antipsychotics.
The following exclusion criteria were applied for both groups: history of
previous psychotic disorder, psychotic symptomatology secondary to an
‘organic’ disorder, psychotic symptoms associated with an affective
psychosis or a borderline personality disorder, substance abuse according
to ICD-10 research criteria, head trauma, neurological illness, serious
medical or surgical illness, being younger than 18 years, inadequate
knowledge of the German language and IQ less than 70 as measured by
the Mehrfachwahl Wortschatz (Multiple Choice Vocabulary) Test Form B
(MWT-B).
All participants provided written informed consent and received
compensation for participating. The studies had permission from the
ethics committee beider Basel (EKBB).
Magnetic resonance imaging acquisition
All anatomical scans were performed on a 3 T magnetic resonance
imaging scanner (Siemens Magnetom Verio, Siemens Healthcare, Erlangen,
Germany) using a 12-channel phased-array radio frequency head coil. For
structural images, a 3D T1-weighted magnetisation-prepared rapid
gradient echo sequence was used with the following parameters: an
inversion time of 1 000 ms, ﬂip angle = 8 degrees, repetition time (TR) = 2 s,
echo time (TE) = 3.37 ms, ﬁeld of view (FOV) = 25.6 cm, acquisition
matrix = 256× 256× 176, resulting in 176 contiguous sagittal slices with
1× 1× 1 mm3 isotropic spatial resolution. All scans were screened for gross
radiological abnormalities by an experienced neuroradiologist.
Genotyping and imputation
DNA was extracted from whole-blood samples using the QIAamp DNA
Blood Maxi kit according to the standard procedures (Qiagen, Chatsworth,
CA, USA). DNA samples were further processed on the Affymetrix Genome-
Wide Human SNP Array 6.0. in one centralised microarray facility as
described in the Genome-Wide Human SNP Nsp/Sty 6.0. User Guide
(Affymetrix, Santa Clara, CA, USA). Generation of SNP calls and array quality
control (QC) were performed using the Affymetrix Genotyping Console
Software 3.0 (Affymetrix). According to the manufacturer’s recommenda-
tion, contrast QC was chosen as QC metric, using the default value of 0.4.
All samples passing QC criteria were subsequently genotyped using the
Birdseed (v2) algorithm, leading to a total of 921 523 genotyped SNPs per
sample. Appropriate SNP QC ﬁltering was applied in the PLINK 1.9
software,36,37 where the gender check in PLINK led to the exclusion of
three individuals.
Population stratiﬁcation was assessed using principal component (PC)
analysis implemented in the EIGENSTRAT software38 to detect genotypic
outliers (with default parameters:46 s.d.'s on any of the top 10 PCs in ﬁve
iterations) and to correct for the potential population substructure by
analysing all array-based pruned, autosomal SNPs. Eight individuals were
identiﬁed as outliers and therefore were excluded from further analyses.
Before autosome-wide genotype imputation, haplotype estimation was
performed using SHAPEITv2 software,39 allowing a per individual and a per
SNP missing rate for observed markers of max. 5%. After pre-phasing,
genotype imputation was performed using IMPUTE v2.3.0 software, which
imputes missing genotypes using a multipopulation reference panel.40,41
The integrated variant callset of 1092 individuals from the 1000 Genomes
Project (release v3 in NCBI build 37/hg19 coordinates, March 2012) served
as panel data (http://mathgen.stats.ox.ac.uk/impute/ALL_1000G_phase1in
tegrated_v3_impute_macGT1.tgz). Only genotype calls exceeding a
probability score of 90% were converted into genotype calls for statistical
analysis using the PLINK 1.9 software.42
PSRS calculation
PSRS were calculated, following the suggestions by Wray et al.,43 by taking
linkage disequilibrium (LD)-pruned loci identiﬁed by the Schizophrenia
Working Group of the PGC in a GWAS of 36 989 schizophrenia patients and
113 075 healthy controls27 (http://www.med. unc.edu/pgc/downloads). A
total of 87 SNPs that could be mapped to one of the top SNPs of the 108
loci associated with schizophrenia and that survived QC were used to
calculate the PSRS. (The following were included: 17 SNPs represented on
the Affymetrix 6.0 Genotyping Array and 70 imputed SNPs (see
Supplementary Table 1). The following were excluded: 7 SNPs that could
not be imputed, 3 SNPs on allosome, 11 insertion/deletion variants and 20
variants in physically dependent genomic regions.). In summary, the
number of risk alleles per person was weighted for each SNP by the
logarithm of its odds ratio as reported in the PGC SZ data set27 and
summed across SNPs44 using the PLINK 1.9 software.36,37 The PSRS was
then corrected for the ﬁrst 20 genotypic PCs and the number of SNPs used
to calculate the PSRS by using the z-transformed residuals of a linear
regression.
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Image processing
Subcortical structures were segmented from T1-weighted magnetisation-
prepared rapid gradient echo images with FMRIB's Integrated Registration
and Segmentation Tool 5.0.4. (FSL-FIRST).45 Raw volumes for the left and
right hippocampi were extracted and separately corrected for intracranial
volume, age, gender, antidepressant intake as dichotomous variable and
CPZ equivalents of antipsychotics by using the z-transformed residuals of a
linear regression. After a separate outlier control for both hippocampal
sides (mean± 3.5 s.d.), which resulting in the exclusion of three individuals,
the mean hippocampal volume was calculated.
Statistical analysis
The R 3.0.2 software46 with the packages stats was used for statistical,
group-related analysis. Χ2-tests or t-tests were used to test the distribution
between diagnosis group and age, sex, handedness, years of education,
IQ, BPRS, SANS, Global Assessment of Functioning, antipsychotics and
antidepressants. Values are presented as mean± s.d. (see Table 1). In
addition, associations between clinical symptoms and PSRS or hippocam-
pal volumes were examined with linear regression analysis. The relation-
ship between corrected PSRS (corrected for the ﬁrst 20 genotypic PCs and
the number of SNPs used to calculate the PSRS) and the corrected bilateral
hippocampal volumes (corrected for intracranial volume, age, gender,
antidepressant intake as dichotomous variable and CPZ equivalents of
antipsychotic doses) was assessed in a linear regression model. We then
ﬁtted a logistic regression using the generalised linear model function in R
with diagnosis status as binary dependent variable and the corrected
bilateral hippocampal volumes and the corrected PSRS score as
independent variables (both having similar variance between groups).
Furthermore, mediation analysis47–49 was conducted to assess the driving
factor of these associations using the R package mediation.50 The indirect
effect was tested using the quasi-Bayesian Monte Carlo method based on
normal approximation and the 95% conﬁdence interval (CI) was obtained
through 1000 simulations.
Table 1. Demographics and clinical characteristics
Characteristics ARMS (n=38) FEP (n= 27) Statistics P-value
Gender M/F (% M) 26/12 (32%) 20/7 (26%) χ2= 0.05 0.83
Mean age in years (s.d.) 23.83 (4.31) 28.33 (7.91) t=− 2.68 0.01
Handedness r/l (% l) 35/3 (8%) 20/7 (26%) χ2= 2.68 0.11
Years of education (s.d.) 13.72 (2.59) 13.76 (3.15) t=− 0.05 0.96
MWT-B (s.d.) 110.73 (13.85) 109.23 (17.88) t= 0.33 0.74
BPRS (s.d.) 37.16 (7.28) 50.33 (15.49) t=− 3.90 0.001
SANS (s.d.) 19.55 (15.31) 24.14 (15.15) t=− 1.13 0.27
GAF (s.d.) 70.11 (12.35) 59.59 (17.07) t= 2.73 0.009
AP no/yes (% y) 38/0 (0%) 17/10 (37%) χ2= 13.91 o0.001
AD no/yes (% y) 20/18 (47%) 20/7 (26%) χ2= 2.23 0.14
Abbreviations: AD, antidepressants; AP, antipsychotics; ARMS, at-risk mental state; BPRS, Brief Psychiatric Rating Scale; F, female; FEP, ﬁrst-episode psychosis;
GAF, Global Assessment of Functioning; l, left; M, male; MWT-B, Mehrfachwahl Wortschatz Test (Multiple Choice Vocabulary) Form B; r, right; SANS, Scale for the
Assessment of Negative Symptoms.
Table 2. Results of linear regression, logistic regression and mediation analyses
Variable Coefﬁcients s.e. Z-value P-value 95% CI lower 95% CI upper
Linear regression: ARMS and FEP
Intercept 0.02 0.12 0.15 0.88 − 0.22 0.26
Hippocampal volumes − 0.42 0.15 − 2.83 0.01 − 0.72 − 0.12
R2= 0.11; comparison with null model: χ2= 7.75, P= 0.01
Linear regression: ARMS only
Intercept − 0.20 0.16 − 1.29 0.21 − 0.52 0.12
Hippocampal volumes − 0.51 0.21 − 2.39 0.02 − 0.94 − 0.08
R2= 0.14; comparison with null model: χ2= 5.60, P= 0.02
Linear regression: FEP only
Intercept 0.32 0.17 1.82 0.08 − 0.04 0.68
Hippocampal volumes − 0.41 0.20 − 2.03 0.05 − 0.83 0.01
R2= 0.14; comparison with null model: χ2= 4.11, P= 0.04
Logistic regression: ARMS and FEP
Intercept − 0.43 0.29 − 1.48 0.14 − 1.01 0.13
PSRS 0.64 0.30 2.11 0.03 0.08 1.29
Hippocampal volumes 0.59 0.37 1.60 0.11 − 0.11 1.36
PSRS x hippocampal volumes − 0.14 0.37 − 0.39 0.70 − 0.88 0.60
Nagelkerk’se-R2= 0.1; c-statistic: 64.4%; comparison with null model: χ2= 5.88,
P= 0.12
Mediation analysis
ACME − 0.03 0.09 − 0.09 0.006
ADE 0.14 0.03 0.02 0.27
Total effect 0.12 0.07 −0.01 0.25
Abbreviations: ARMS, at-risk mental state; ACME, average causal mediation effect; ADE, average direct effect; CI, conﬁdence interval; FEP, ﬁrst-episode
psychosis; PSRS, Polygenic Schizophrenia-related Risk Score.
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RESULTS
Clinical and demographic characteristics
There were no signiﬁcant differences among the investigated
groups with respect to gender (P= 0.83), handedness (P= 0.11),
years of education (P= 0.96) MWT-B (P= 0.74), SANS (P= 0.27) and
number of individuals treated with antidepressants (P= 0.14).
There were signiﬁcant between-group differences in age (P= 0.01),
BPRS (P= 0.001), Global Assessment of Functioning (P= 0.009) and
the number of patients treated with antipsychotics (Po0.001;
Table 1). None of the clinical characteristics was associated with
the PSRS or the hippocampal volumes at the time of MR scanning.
Association between diagnosis, PSRS and hippocampal volume
Linear regression analysis revealed a signiﬁcant relationship
between the PSRS and hippocampal volumes (β=− 0.42,
P= 0.01, 95% CI = (−0.72 to − 0.12), Table 2) in our total sample
and the subgroup of ARMS individuals (β=− 0.51, P= 0.02, 95%
CI = (−0.94 to − 0.08), Figure 1, Table 2) and FEP patients separately
(β=− 0.41, P= 0.05, 95% CI = (−0.83 to 0.01), Figure 1, Table 2). To
further analyse this association in the total sample, we performed
a logistic regression analysis. A signiﬁcant main effect of the PSRS
on the log odds of an individual being assigned to the FEP state
was observed (β= 0.64, P= 0.03, 95% CI = (0.08–1.29), Table 2,
Figure 2). In addition, neither a main effect of the hippocampal
volumes (β= 0.59, P= 0.11, 95% CI = (−0.11 to 1.36), Table 2) nor an
interaction effect of PSRS and hippocampal volumes (β=− 0.14,
P= 0.70, 95% CI = (−0.88 to 0.60), Table 2) on the log odds was
detected. Therefore, a higher PSRS score is associated with a
higher likelihood that an individual would be assigned to the
group of FEP individuals than to the group of ARMS individuals.
Moreover, the mediation analysis indicated no mediating role of
the hippocampal volumes between PSRS and group assignment
(β=− 0.03, P= 0.09, 95% CI = (−0.09 to 0.006), Figure 3, Table 2).
And, the direct effect of PSRS on group assignment when
controlling for hippocampal volumes remained signiﬁcant
(β= 0.14, P= 0.03, 95% CI = (0.02–0.27), Figure 3, Table 2).
DISCUSSION
To our knowledge, this is the ﬁrst study to analyse the association
between a PSRS, hippocampal volumes and the onset of
psychosis. We found a negative association between the
hippocampal volumes and the PSRS across ARMS individuals
and FEP patients, derived from the top hits within genome-wide
signiﬁcant loci identiﬁed by the large GWAS analysis from the
Psychiatric Genomics Consortium.27 Moreover, a higher PSRS was
signiﬁcantly associated with a higher probability of being assigned
to the FEP group than to the ARMS group.
We demonstrate that reduced hippocampal volumes were
associated with higher PSRS in the total sample of ARMS
individuals and FEP patients as well as for each group separately.
This association might suggest that schizophrenia-related SNPs
Figure 3. Mediation analysis scheme. Indirect effect of PSRS on
group assignment through hippocampal volumes and direct effect
of PSRS on group assignment. P-values are reported as estimate of
signiﬁcance. PSRS, Polygenic Schizophrenia-related Risk Score.
Figure 1. Linear regression analysis of PSRS and hippocampal
volumes. Standardised residuals of the PSRS are adjusted for the
ﬁrst 20 genotypic PCs and the number of SNPs used to calculate the
PSRS. Standardised residuals of the mean hippocampal volume are
adjusted on each side separately for ICV, age, gender antidepressant
intake and CPZ equivalents. Red dashed line, regression line with
95% conﬁdence interval of FEP cohort; blue dot-dashed line,
regression line with 95% conﬁdence interval of ARMS cohort. ARMS,
at-risk mental state; CPZ, chlorpromazine; FEP, ﬁrst-episode psycho-
sis; ICV, intracranial volume; PC, principal component; PSRS,
Polygenic Schizophrenia-Related Risk Score; SNP, single-nucleotide
polymorphism.
Figure 2. Plot of estimated probability for being FEP versus PSRS.
The standardised residuals of the PSRS are adjusted for the ﬁrst 20
genotypic PCs, and the number of SNPs used to calculate the PSRS
are plotted against estimated probability of logistic regression. Black
dashed line, regression line with 95% conﬁdence interval of FEP and
ARMS cohorts. ARMS, at-risk mental state; FEP, ﬁrst-episode psychosis;
PC, principal component; PSRS, Polygenic Schizophrenia-Related
Risk Score; SNP, single-nucleotide polymorphism.
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are directly linked to smaller hippocampi. However, such a direct
link cannot be inferred from our results because other factors such
as stressful life events51 or neuropsychiatric medication52,53 have
been shown to modulate the volumes of the hippocampus. It
should be further noted that volumetric alterations in the
hippocampus have been linked to psychotic symptoms and
cognitive deﬁcits of schizophrenia,54 a core function of the
hippocampus, and ARMS individuals already show some deﬁcits in
verbal ﬂuency and memory functioning.5,16
We also observed that a higher PSRS was associated with a
higher likelihood of an individual being assigned to the FEP group
than to the ARMS group. This ﬁnding might reﬂect the fact that
only ~ 30% of ARMS individuals are correctly predicted to develop
psychosis4,5 and thus might not have a high PSRS. Moreover, the
hippocampal volumes were not identiﬁed as mediator between
PSRS and group assignment. Therefore, further studies should
analyse whether the PSRS could be used to further characterise
those ARMS individuals who will develop psychosis and whether
ARMS individuals with a higher PSRS are more likely to develop
psychosis. Owing to the limited number of ARMS individuals with
later transition to psychosis, we could not investigate whether this
PSRS might be a vulnerability trait for transition. Nevertheless, we
observed that four of our six ARMS individuals who (until now)
have developed psychosis had a PSRS above the median of the
total sample. Therefore, further longitudinal studies should
examine whether a combination of clinical, genetic, environmen-
tal, neuroimaging and neurocognitive markers can improve the
prediction rate for transition to psychosis.
The absence of a signiﬁcant association between hippocampal
volumes and being in either the ARMS or FEP groups supports
several ﬁndings of similar volumes.10,11,17 Furthermore, it has been
reported that the volumes of the hippocampus were negatively
associated with negative symptoms in ARMS individuals and
schizophrenia patients55–58 and that the hippocampal–prefrontal
pathway was linked to negative symptoms and cognitive deﬁcits
in schizophrenia.59 Therefore, it might be speculated that the
similar levels of negative symptoms in FEP patients and ARMS
individuals might partially underlie the absence of volumetric
hippocampal differences. However, future functional and struc-
tural connectivity studies should further examine the hippocam-
pus and the inter-related cortical and subcortical regions,
including the dorsolateral prefrontal cortex to assess possible
impairments in neuronal networks in schizophrenia. Moreover, it
was demonstrated that a PRS was associated with negative
symptoms and not positive symptoms in a large sample of
adolescence from the general population.60 Therefore, it might be
especially important to focus on the combined analysis of clinical,
genetic and neuroimaging data.
Limitations
There are some limitations to bear in mind concerning the results
of this study. First, the sample size is relatively small. However, the
groups are homogeneous with regard to genetic background and
clinical characteristics related to disease status and prognosis.61
This makes confounding effects of disease duration or anti-
psychotic medication unlikely. In addition, polygenic risk scores
derived from large GWAS generate robust estimators,62 which can
be used in small samples. Second, the PSRS explains only a small
amount of variance in liability to schizophrenia and cannot be
considered as a classiﬁer between ARMS individuals and FEP
patients. Thus, prediction of actual transition to psychosis is not
possible; however, this aspect will be further investigated when
we have obtained enough follow-up data. Third, as the aim of the
present study was to include patients with a ﬁrst psychotic
episode independent of the underlying diagnosis according to
ICD/DSM classiﬁcation systems, no conclusions can be drawn
regarding non-affective versus affective psychoses speciﬁcally.
CONCLUSION
In summary, this is the ﬁrst study to evaluate a negative
association between a PSRS and hippocampal volumes in ARMS
individuals and FEP patients. Our ﬁndings suggest that the
combination of a subset of schizophrenia risk variants is related to
hippocampal volume and that higher values of this genome-wide
signiﬁcant PSRS (but not hippocampal volume or the interaction
effect) are associated to FEP status than to the ARMS. These
ﬁndings imply that FEP patients have a higher genetic risk for
schizophrenia than the total cohort of ARMS individuals, and
encourage further studies on the use of PSRS as an additional
marker in the prediction of psychosis from the prodromal state.
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